ALLN-346

A Novel Approach to Hyperuricemia

ALLN-346 is being developed for the management of hyperuricemia and gout. The enzyme has the potential to decrease the amount of uric acid available to form urate crystals in the kidneys and joints. By doing so, it may help to reduce the pain, inflammation and swelling commonly associated with gout, significantly enhancing quality of life in patients with a high burden of uric acid.